Low-Frequency Repetitive Transcranial Magnetic Stimulation over Right Dorsolateral Prefrontal Cortex in Parkinson’s Disease

Table 3

Secondary outcome comparisons between active and sham rTMS groups.

		UPDRS part III	UPDRS	NMSQ	HRSD	PSQI	MoCA
Active	T0	27.84 (8.96)	48.58 (15.90)	12.05 (4.61)	13.26 (6.90)	9.63 (4.87)	24.37 (3.53)
	T1	21.95 (7.99)^ab	39.32 (12.50)^ab	9.53 (4.14)^ab	8.79 (5.19)^ab	7.63 (4.42)^b	26.37 (2.67)^ab
	T2	22.26 (7.32)^ab	39.47 (11.44)^ab	10.37 (4.18)^ab	10.32 (5.33)^ab	7.11 (3.91)^ab	26.58 (3.67)^ab
	T3	25.68 (8.58)^ab	43.05 (14.82)	11.05 (4.4)3^b	12.32 (6.47)^a	7.3 (3.89)^ab	26.58 (3.04)^ab
	T4	27.00 (9.46)	44.26 (14.81)	11.53 (4.41)	12.74 (6.99)	8.00 (4.11)	26.47 (3.17)^ab
Sham	T0	29.00 (13.16)	43.71 (19.13)	8.79 (5.16)	15.86 (7.12)	7.57 (3.25)	22.57 (3.13)
	T1	28.64 (12.57)	43.43 (18.47)	8.57 (5.69)	15.50 (6.78)	7.50 (3.06)	22.93 (2.92)
	T2	28.64 (13.84)	43.43 (19.86)	8.43 (5.46)	15.57 (7.23)	7.57 (3.13)	22.71 (2.97)
	T3	28.79 (13.43)	43.71 (21.36)	9.86 (5.33)	15.36 (6.92)	8.36 (3.95)	22.29 (2.87)
	T4	28.79 (13.11)	43.57 (21.18)	9.93 (5.26)	15.36 (7.22)	8.43 (3.84)	22.14 (2.91)
	14.215	3.153	3.461	13.916	5.052	9.192
	<0.001	0.057	0.038	<0.001	0.006	<0.001

Abbreviations: H-Y stage: Hoehn and Yahr stage; LED: levodopa equivalent dose; UPDRS: Unified Parkinson’s Disease Rating Scale; NMSQ: Nonmotor Symptom Questionnaire; HRSD: Hamilton Rating Scale for Depression; PSQI: Pittsburgh Sleep Quality Index; MoCA: Montreal Cognitive Assessment. T0: baseline; T1: after treatment; T2: 1 month; T3: 3 months; T4: 6 months. and values for rANOVA interaction (time and group) with adjustment for nonsphericity. ^aSignificant difference from baseline. ^bSignificant difference between groups.